| certoparin versus unfractionated heparin | |||
| Schmitz-Huebner, 1984 | Certoparin (dose 1 and dose 2) b.i.d. versus UFH 10 000 units | Abdominal surgery | Blind Follow-up duration: 1 month |
| Sasahara, 1986 | Certoparin 3000 + DHE versus UFH 10 000 units +DHE | Abdominal surgery | Blind Follow-up duration: 7 days |
| Voigt, 1986 | Certoparin 3000 + DHE versus UFH 10 000 units | Abdominal surgery | Blind Follow-up duration: 10 days |
| Welzel, 1988 | Certoparin 2500 + DHE versus UFH 10 000 units+DHE | Abdominal surgery | Open Follow-up duration: 7 days |
| Kakkar, 1989 | Certoparin 3000 + DHE versus UFH 10 000 units+DHE | Abdominal surgery | Blind |
| Adolf, 1989 | Certoparin 3000 versus UFH 15 000 units | Abdominal surgery | Blind Follow-up duration: 1 month |
| Baumgartner, 1989 | Certoparin 3000 + DHE versus UFH 5 000 units+DHE | Abdominal surgery | Blind Follow-up duration: 10 days |
| Hoffmann and Largiade, 1990 | Certoparin 3000 + DHE versus UFH 10 000 units | Abdominal surgery | NA |
| Koppenhagen, 1990 | Certoparin 3000 anti Xa units versus UFH 15 000 units | Abdominal surgery | Blind |
| Schielke, 1991 | Certoparin 3000 anti Xa units + DHE versus UFH 10 000 units + DHE | Abdominal surgery | Open |
| Koppenhagen, 1992 | Certoparin 3000 anti Xa units versus UFH 15 000 units | Abdominal surgery | Blind |
| dalteparin versus unfractionated heparin | |||
| Bergqvist, 1986 | Dalteparin 5000 versus UFH 10 000 units | Abdominal surgery | Blind Follow-up duration: 1 month |
| Onarheim, 1986 | Dalteparin 5000 versus UFH 10 000 units | Abdominal surgery | Blind Follow-up duration: 1 month |
| Koller, 1986 | Dalteparin 7500 versus UFH 10 000 units | Abdominal surgery | Blind Follow-up duration: 30 days |
| Koller, 1986 | Dalteparin 2500 versus UFH 10 000 units | Abdominal surgery | Blind Follow-up duration: 30 days |
| Fricker, 1988 | Dalteparin 5000 versus UFH 15 000 units | Abdominopelvic surgery | Open Follow-up duration: 1-2 months |
| Bergqvist, 1988 | Dalteparin 5000 versus UFH 10 000 units | Abdominal surgery | Blind Follow-up duration: 1 month |
| Caen, 1988 | Dalteparin 2500 versus UFH 10 000 units | Abdominal surgery | Blind Follow-up duration: 1 month |
| Hartl, 1990 | Dalteparin 2500 versus UFH 10 000 units | Abdominal surgery | Blind Follow-up duration: > 7 days |
| Kakkar, 1993 | Dalteparin 2500 anti Xa units versus UFH 10 000 units | Abdominal surgery | Blind |
| enoxaparin versus unfractionated heparin | |||
| McLeod (Canadian), 1995 | Enoxaparin 4000 anti Xa units versus UFH 15 000 units | Colorectal surgery | Blind |
| Gonzalez, 1996 | Bemiparin 2500 anti Xa units versus UFH 10 000 units | Abdominal surgery | Blind |
| extended prophylaxis versus standard prophylaxis | |||
| Lausen, 1998 | Tinzaparin 3500 UI/qd sc for 28 days started in preop versus Tinzaparin 3500 UI/qd + GES for 1 week started in preop | >18 years, open major abdominal surgery and non cardiac thoracic surgery of >1hour duration. | Open, blinded evaluation Follow-up duration: 28 days |
| ENOXACAN II (Bergqvist), 2002 | Enoxaparin 40 mg UI/qd sc for 25-31 days started in preop versus Enoxaparin 40 mg IU/qd sc for 6 to 10 days (GES optional) started in preop | > 40 years, open major abdominal oncologic elective surgery of >45 minutes duration (includes gynecological surgery) | double blind Follow-up duration: 3 months |
| FAME (Rasmussen), 2006 | Dalteparin 5000 UI/qd SC for 28 days started in preop versus Dalteparin 5000 UI/qd SC for 7 days + GES started in preop | > 18 years, major abdominal surgery of >1 hour duration | Open, blinded evaluation Follow-up duration: 3 months |
| fondaparinux versus enoxaparin | |||
| PEGASUS, 2005 | once-daily subcutaneous injections of fondaparinux 2·5 mg started 6 h after surgery for 5–9 days versus once-daily subcutaneous injections of dalteparin 5000 units for 5–9 days (2500 units each, given 2 h before surgery and 12 h after the preoperative administration) | patients undergoing major abdominal surgery | double blind Follow-up duration: 10 days (30 days) 22 countries |
| fondaparinux versus placebo (on top intermittent pneumatic comp.) | |||
| APOLLO (Turpie), 2007 | fondaparinux 2.5 mg s.c. for 5-9 days, starting 6-8 h postoperatively + intermittent pneumatic compression versus placebo s.c. for 5-9 days, starting 6-8 h postoperatively + intermittent pneumatic compression | Patients aged at least 40 years undergoing abdominal surgery | double blind Follow-up duration: 10 days US |
| nadroparin versus unfractionated heparin | |||
| EFS, 1988 | Nadroparin 2850 versus UFH 15 000 units | Abdominal surgery | Open Follow-up duration: 1 month |
| parnaparin versus unfractionated heparin | |||
| Catania, 1988 | Parnaparin 3200 versus UFH 15 000 units | Abdominal surgery | Open |
| Salcuni, 1988 | Parnaparin 3200 versus UFH 15 000 units | Abdominal surgery | Open |
| Verardi, 1989 | Parnaparin 6400 versus UFH 10 000 units | Abdominal/urological surgery | NA |
| Garcea, 1992 | Parnaparin 3200 anti Xa units versus UFH 15 000 units | Abdominal surgery | Open |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
